Начало・Списък с акции・Roche Holding AG

Roche Holding AG

Затворен

СекторЗдравеопазване

273.2 -1.8

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

273.2

Максимум

275.8

Ключови измерители
By Trading Economics
Приходи	2B
Продажби	31B
P/E Средно за сектора	26.266 39.564
Дивидентна доходност	3.53
Марж на печалбата	6.588
Служители	103,249
EBITDA	6B

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	3.53% 2.40%

Пазарни показатели
By TradingEconomics
Пазарна капитализация	204B
Предишно отваряне	275
Предишно затваряне	273.2

Настроения в новините

By Acuity

18%

82%

36 / 376 Класиране в Healthcare

Roche Holding AG Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.06.2025 г., 08:25 ч. UTC

Придобивния, сливания и поглъщания

EQT, Sanofi Co-Led $135 Million Funding Round for Spanish Biotech Company SpliceBio

12.05.2025 г., 02:16 ч. UTC

Значими двигатели на пазара

Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs

24.04.2025 г., 07:30 ч. UTC

Печалби

Roche Sales Gain on Boost From Key Drugs Amid U.S. Production Push -- Update

24.04.2025 г., 05:31 ч. UTC

Печалби

Roche Sales Rise Boosted By Key Drugs

9.04.2025 г., 09:39 ч. UTC

Значими двигатели на пазара

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

12.03.2025 г., 09:23 ч. UTC

Значими двигатели на пазара

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

30.01.2025 г., 09:36 ч. UTC

Печалби

Roche Expects Growth to Continue This Year After Sales, Earnings Beat Forecasts -- Update

30.01.2025 г., 06:32 ч. UTC

Печалби

Roche Expects Sales, Earnings Growth After Better-Than-Expected Results

16.06.2025 г., 08:55 ч. UTC

Горещи акции

Stocks to Watch: Victoria's Secret, Renault, U.S. Steel, Sarepta -- WSJ

3.06.2025 г., 07:51 ч. UTC

Пазарно говорене

Roche Unlikely to Get Revenue Boost From Tecentriq Combination With Lurbinectedin -- Market Talk

21.05.2025 г., 07:20 ч. UTC

Пазарно говорене

Roche Lymphoma Drug Columvi Dealt Setback by FDA Committee -- Market Talk

2.05.2025 г., 06:25 ч. UTC

Пазарно говорене

Печалби

Roche Shows Pipeline Progress But Near-Term Risks Remain -- Market Talk

24.04.2025 г., 09:39 ч. UTC

Пазарно говорене

Печалби

Roche's Pipeline in Focus After Solid Results -- Market Talk

24.04.2025 г., 09:24 ч. UTC

Пазарно говорене

Печалби

Roche's Reiterated Outlook Looks Reassuring -- Market Talk

24.04.2025 г., 09:18 ч. UTC

Пазарно говорене

Печалби

Roche's Results Are Solid -- Market Talk

24.04.2025 г., 05:16 ч. UTC

Топ новини

Roche Sales Rise, Boosted By Key Drugs

22.04.2025 г., 10:51 ч. UTC

Топ новини

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

15.04.2025 г., 09:55 ч. UTC

Пазарно говорене

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

9.04.2025 г., 10:03 ч. UTC

Пазарно говорене

Печалби

Roche's Eye Drug in Focus for 1Q Earnings -- Market Talk

9.04.2025 г., 07:23 ч. UTC

Пазарно говорене

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

3.04.2025 г., 08:41 ч. UTC

Пазарно говорене

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3.04.2025 г., 07:51 ч. UTC

Пазарно говорене

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

31.03.2025 г., 09:31 ч. UTC

Горещи акции

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

13.03.2025 г., 07:46 ч. UTC

Пазарно говорене

Roche's Zealand Pharma Deal Signals Commitment to Obesity Drug Market -- Market Talk

12.03.2025 г., 16:34 ч. UTC

Топ новини

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

12.03.2025 г., 08:51 ч. UTC

Пазарно говорене

Roche's Multiple-Sclerosis Drug Sales Potential Fuels Rating Upgrade -- Market Talk

12.03.2025 г., 08:18 ч. UTC

Пазарно говорене

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

13.02.2025 г., 11:43 ч. UTC

Пазарно говорене

Roche's Growth Fueled by Key Drugs, Promising Pipeline -- Market Talk

30.01.2025 г., 07:56 ч. UTC

Пазарно говорене

Печалби

Roche Delivered Solid Results But Diagnostics' Profitability Disappoints -- Market Talk

30.01.2025 г., 06:04 ч. UTC

Печалби

Roche Expects 2025 EPS Growth in High Single Digit Range at Constant Currency

Roche Holding AG Прогноза

Настроение

By Acuity

36 / 376 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

Roche Holding AG

Преглед

Промяна на цената на акция

Ключови измерители

Дивиденти

Пазарни показатели

Настроения в новините

Roche Holding AG Графика

Свързани новини

Roche Holding AG Прогноза

Настроение

Финанси

Относно Roche Holding AG